Institute of Pathology and Southwest Cancer Center and Key Laboratory of Tumor Immunopathology of Ministry of Education of China, Southwest Hospital, Third Military Medical University (Army Medical University), Chongqing, China.
Department of General Surgery, Southwest Hospital, Third Military Medical University, Chongqing, China.
Cancer Res. 2018 Jun 1;78(11):3041-3053. doi: 10.1158/0008-5472.CAN-17-3776. Epub 2018 Mar 16.
Potassium ion channels are emerging as promalignant factors involved in cancer progression. In this study, we found that invading human gastric cancer cells express high levels of inwardly rectifying potassium channel 2.1 (Kir2.1). Silencing Kir2.1 markedly reduced the invasive and metastatic capabilities as well as the epithelial-mesenchymal transition (EMT) of gastric cancer cells. The promalignant nature of Kir2.1 in gastric cancer cells was independent of potassium permeation but relied on its interaction with serine/threonine-protein kinase 38 (Stk38) to inhibit ubiquitination and degradation of mitogen-activated protein kinase kinase kinase 2 (MEKK2). Degradation of MEKK2 was mediated by small mothers against decapentaplegic-specific E3 ubiquitin protein ligase 1 (Smurf1), which resulted in activation of the MEK1/2-ERK1/2-Snail pathway in gastric cancer cells. In human gastric cancer tissues, expression was high and positively correlated with invasion depth and metastatic status of the tumors as well as poor overall patient survival. Cox regression analysis identified Kir2.1 as an independent prognostic indicator for patients with gastric cancer. Our results suggest that Kir2.1 is an important regulator of gastric cancer malignancy and acts as a novel prognostic marker and a therapeutic target for gastric cancer. Kir2.1 contributes to invasion and metastasis by a noncanonical ion permeation-independent signaling pathway and may act as a novel prognostic marker and therapeutic target for gastric cancer. .
钾离子通道正在成为涉及癌症进展的促癌因素。在这项研究中,我们发现侵袭性人类胃癌细胞表达高水平的内向整流钾通道 2.1(Kir2.1)。沉默 Kir2.1 显著降低了胃癌细胞的侵袭和转移能力以及上皮-间充质转化(EMT)。Kir2.1 在胃癌细胞中的促癌性质不依赖于钾渗透,而是依赖于其与丝氨酸/苏氨酸蛋白激酶 38(Stk38)的相互作用,以抑制丝裂原活化蛋白激酶激酶激酶 2(MEKK2)的泛素化和降解。MEKK2 的降解是由小 mothers against decapentaplegic-specific E3 泛素蛋白连接酶 1(Smurf1)介导的,这导致胃癌细胞中 MEK1/2-ERK1/2-Snail 通路的激活。在人类胃癌组织中,表达水平较高,与肿瘤的浸润深度和转移状态以及患者总体生存状况呈正相关。Cox 回归分析确定 Kir2.1 是胃癌患者的独立预后指标。我们的结果表明,Kir2.1 是胃癌恶性程度的重要调节剂,可作为胃癌的新型预后标志物和治疗靶点。Kir2.1 通过非典型的离子渗透非依赖性信号通路促进侵袭和转移,可能成为胃癌的新型预后标志物和治疗靶点。